GILEAD SCIENCES, INC. (GILD) FY2024 Q1 Statement of Cash Flows

Income StatementCash FlowBalance Sheet

Statement of Cash Flows

2024-01-01 to 2024-03-31

Swipe to see the full flow
GILEAD SCIENCES, INC. cash flow reconciliation, Jan 1, 2024 through Mar 31, 2024One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Calculated remaining financing cash flows are purple; remaining operating and investing bundles are gray. Their underlying inflows and outflows are not separately identified. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Acquired in-process research and development expenses → operating reconciliation: $4,131,000,000.00In-process research and development impairment → operating reconciliation: $2,430,000,000.00Amortization expense → operating reconciliation: $596,000,000.00Stock-based compensation expense → operating reconciliation: $187,000,000.00Other → operating reconciliation: $119,000,000.00Depreciation expense → operating reconciliation: $94,000,000.00Accounts payable → operating reconciliation: $72,000,000.00Net loss from equity securities → operating reconciliation: $14,000,000.00operating reconciliation → Net cash from operating activities: $2,219,000,000.00operating reconciliation → Net (loss) income: $4,170,000,000.00operating reconciliation → Deferred income taxes: $723,000,000.00operating reconciliation → Income tax assets and liabilities, net: $208,000,000.00operating reconciliation → Accrued and other liabilities: $175,000,000.00operating reconciliation → Accounts receivable, net: $66,000,000.00operating reconciliation → Inventories: $45,000,000.00operating reconciliation → Prepaid expenses and other: $37,000,000.00Proceeds from sales of marketable debt securities → investing reconciliation: $2,265,000,000.00Proceeds from maturities of marketable debt securities → investing reconciliation: $327,000,000.00Other → investing reconciliation: $5,000,000.00investing reconciliation → Acquisitions, including in-process research and development, net of cash acquired: $4,043,000,000.00investing reconciliation → Purchases of equity securities: $410,000,000.00investing reconciliation → Purchases of marketable debt securities: $244,000,000.00investing reconciliation → Capital expenditures: $105,000,000.00investing reconciliation → Remaining investing cash flows, net (calculated): $2,000,000.00Net cash used in financing activities → financing reconciliation: $1,361,000,000.00Proceeds from issuances of common stock → financing reconciliation: $146,000,000.00financing reconciliation → Payments of dividends: $990,000,000.00financing reconciliation → Repurchases of common stock under repurchase programs: $400,000,000.00financing reconciliation → Other: $116,000,000.00financing reconciliation → Remaining financing cash flows, net (calculated): $1,000,000.00Net cash used in investing activities → investing reconciliation: $2,207,000,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $6,085,000,000.00Net cash from operating activities → Cash sources and uses: $2,219,000,000.00Cash sources and uses → Exchange-rate effect: $18,000,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $4,718,000,000.00Cash sources and uses → Net cash used in investing activities: $2,207,000,000.00Cash sources and uses → Net cash used in financing activities: $1,361,000,000.00Income tax assets and liabilities, net: -$208,000,000.00Income tax balances−$208.00 MNet (loss) income: -$4,170,000,000.00Net (loss) income−$4.17 BAcquired in-process research and development expenses: $4,131,000,000.00Acquired IPR&D written off+$4.13 BAccrued and other liabilities: -$175,000,000.00Accrued liabilities−$175.00 MAmortization expense: $596,000,000.00Amortization expense+$596.00 MOther: $119,000,000.00Other non-cash items+$119.00 MStock-based compensation expense: $187,000,000.00Stock-based compensation+$187.00 MNet loss from equity securities: $14,000,000.00Equity securities, net+$14.00 MIn-process research and development impairment: $2,430,000,000.00Indefinite intangible impairment+$2.43 BAccounts payable: $72,000,000.00Accounts payable+$72.00 MDeferred income taxes: -$723,000,000.00Deferred income taxes−$723.00 MPrepaid expenses and other: -$37,000,000.00Prepaid & other assets−$37.00 MInventories: -$45,000,000.00Inventories−$45.00 MDepreciation expense: $94,000,000.00Depreciation expense+$94.00 MAccounts receivable, net: -$66,000,000.00Accounts receivable−$66.00 MNet cash from operating activities: $2,219,000,000.00Operating cash+$2.22 Boperating reconciliation: $7,643,000,000.00Proceeds from issuances of common stock: $146,000,000.00Common stock issued+$146.00 MPayments of dividends: -$990,000,000.00Dividends paid−$990.00 MRepurchases of common stock under repurchase programs: -$400,000,000.00Common stock repurchases−$400.00 MOther: -$116,000,000.00Other financing, net−$116.00 MRemaining financing cash flows, net (calculated): -$1,000,000.00Remaining financing (calculated)−$1.00 MNet cash used in financing activities: -$1,361,000,000.00. Cash required to fund net payments.Financing cash−$1.36 Bfinancing reconciliation: $1,507,000,000.00Purchases of equity securities: -$410,000,000.00Other investment purchases−$410.00 MPurchases of marketable debt securities: -$244,000,000.00AFS securities purchases−$244.00 MCapital expenditures: -$105,000,000.00PP&E purchases−$105.00 MAcquisitions, including in-process research and development, net of cash acquired: -$4,043,000,000.00Acquisitions, net of cash−$4.04 BOther: $5,000,000.00Other investing, net+$5.00 MProceeds from sales of marketable debt securities: $2,265,000,000.00AFS securities sales+$2.27 BProceeds from maturities of marketable debt securities: $327,000,000.00AFS securities maturities+$327.00 MRemaining investing cash flows, net (calculated): -$2,000,000.00Remaining investing (calculated)−$2.00 MNet cash used in investing activities: -$2,207,000,000.00. Cash required to fund net payments.Investing cash−$2.21 Binvesting reconciliation: $4,804,000,000.00Cash sources and uses: $8,304,000,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $6,085,000,000.00Beginning cash$6.09 BEnding cash: Cash, cash equivalents, and restricted cash: $4,718,000,000.00Ending cash$4.72 BExchange-rate effect: -$18,000,000.00FX effect−$18.00 MCASH RECONCILIATIONOperatingflowsInvestingflowsFinancingflowsNet loss −$4.17B + net operating adjustments $6.39B = operating cash +$2.22BFree cash flow$2.11 BOperating cash − cash spent on PP&ECash flow / Net incomeNot meaningfulOperating cash flow ÷ net incomeNet cash change−$1.37 BEnding cash − beginning cash
Chart details

GILEAD SCIENCES, INC. cash flow reconciliation, Jan 1, 2024 through Mar 31, 2024

Cash flows for Jan 1, 2024 through Mar 31, 2024. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2023. Ending cash: Mar 31, 2024. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2023
6,085,000,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
2,219,000,000 US dollars. Net cash provided.
Income tax assets and liabilities, net
negative 208,000,000 US dollars
Net (loss) income
negative 4,170,000,000 US dollars
Acquired in-process research and development expenses
4,131,000,000 US dollars
Accrued and other liabilities
negative 175,000,000 US dollars
Amortization expense
596,000,000 US dollars
Other
119,000,000 US dollars
Stock-based compensation expense
187,000,000 US dollars
Net loss from equity securities
14,000,000 US dollars
In-process research and development impairment
2,430,000,000 US dollars
Accounts payable
72,000,000 US dollars
Deferred income taxes
negative 723,000,000 US dollars
Prepaid expenses and other
negative 37,000,000 US dollars
Inventories
negative 45,000,000 US dollars
Depreciation expense
94,000,000 US dollars
Accounts receivable, net
negative 66,000,000 US dollars
Investing activities
negative 2,207,000,000 US dollars. Net cash used. The remaining amount is calculated by subtracting the other displayed items from the investing total. The filing's tagged investing lines do not add up to the investing total; this is the difference. It may combine inflows and outflows.
Purchases of equity securities
negative 410,000,000 US dollars
Purchases of marketable debt securities
negative 244,000,000 US dollars
Capital expenditures
negative 105,000,000 US dollars
Acquisitions, including in-process research and development, net of cash acquired
negative 4,043,000,000 US dollars
Other
5,000,000 US dollars
Proceeds from sales of marketable debt securities
2,265,000,000 US dollars
Proceeds from maturities of marketable debt securities
327,000,000 US dollars
Remaining investing cash flows, net (calculated)
negative 2,000,000 US dollars
Financing activities
negative 1,361,000,000 US dollars. Net cash used. The remaining amount is calculated by subtracting the other displayed items from the financing total. The filing's tagged financing lines do not add up to the financing total; this is the difference. It may combine inflows and outflows.
Proceeds from issuances of common stock
146,000,000 US dollars
Payments of dividends
negative 990,000,000 US dollars
Repurchases of common stock under repurchase programs
negative 400,000,000 US dollars
Other
negative 116,000,000 US dollars
Remaining financing cash flows, net (calculated)
negative 1,000,000 US dollars
Operating adjustment reconciliation
7,643,000,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing displayed reconciliation
1,507,000,000 US dollars. Intermediate calculation joining the displayed items and the calculated net remainder. It does not establish gross cash receipts or payments and is not an additional cash flow.
investing displayed reconciliation
4,804,000,000 US dollars. Intermediate calculation joining the displayed items and the calculated net remainder. It does not establish gross cash receipts or payments and is not an additional cash flow.
Exchange-rate effect
negative 18,000,000 US dollars
Ending cash on Mar 31, 2024
4,718,000,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
8,304,000,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
negative 1,367,000,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
Operating cash flow
2,219,000,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
105,000,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
2,114,000,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net loss −$4.17B + net operating adjustments $6.39B = operating cash +$2.22B. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 2,219,000,000 US dollars minus 105,000,000 US dollars equals 2,114,000,000 US dollars.
GILEAD SCIENCES, INC. (GILD) FY2024 Q1 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!